nodes	percent_of_prediction	percent_of_DWPC	metapath
Nilotinib—ABCB1—ovarian cancer	0.102	1	CbGaD
Nilotinib—ABCG2—Topotecan—ovarian cancer	0.0534	0.193	CbGbCtD
Nilotinib—ABCG2—Paclitaxel—ovarian cancer	0.0264	0.0956	CbGbCtD
Nilotinib—ABCG2—Carboplatin—ovarian cancer	0.0249	0.09	CbGbCtD
Nilotinib—ABCB1—Topotecan—ovarian cancer	0.0193	0.0696	CbGbCtD
Nilotinib—ABCG2—Docetaxel—ovarian cancer	0.0191	0.0691	CbGbCtD
Nilotinib—ABCG2—Doxorubicin—ovarian cancer	0.0143	0.0515	CbGbCtD
Nilotinib—CYP2C8—Paclitaxel—ovarian cancer	0.0141	0.0509	CbGbCtD
Nilotinib—ABCB1—Vinorelbine—ovarian cancer	0.0136	0.0491	CbGbCtD
Nilotinib—CYP2D6—Vinorelbine—ovarian cancer	0.0128	0.0462	CbGbCtD
Nilotinib—CYP3A4—Topotecan—ovarian cancer	0.0115	0.0417	CbGbCtD
Nilotinib—CYP2B6—Doxorubicin—ovarian cancer	0.01	0.0362	CbGbCtD
Nilotinib—CYP2C9—Paclitaxel—ovarian cancer	0.00983	0.0355	CbGbCtD
Nilotinib—ABCB1—Paclitaxel—ovarian cancer	0.00954	0.0345	CbGbCtD
Nilotinib—CYP3A4—Vinorelbine—ovarian cancer	0.00813	0.0294	CbGbCtD
Nilotinib—ABCB1—Docetaxel—ovarian cancer	0.00689	0.0249	CbGbCtD
Nilotinib—CYP3A4—Paclitaxel—ovarian cancer	0.00571	0.0206	CbGbCtD
Nilotinib—ABCB1—Doxorubicin—ovarian cancer	0.00514	0.0186	CbGbCtD
Nilotinib—CYP2D6—Doxorubicin—ovarian cancer	0.00484	0.0175	CbGbCtD
Nilotinib—CYP3A4—Docetaxel—ovarian cancer	0.00413	0.0149	CbGbCtD
Nilotinib—EPHB2—Irinotecan—Topotecan—ovarian cancer	0.00363	0.738	CbGdCrCtD
Nilotinib—CYP3A4—Doxorubicin—ovarian cancer	0.00308	0.0111	CbGbCtD
Nilotinib—HCK—decidua—ovarian cancer	0.000822	0.00543	CbGeAlD
Nilotinib—TEK—embryo—ovarian cancer	0.000811	0.00535	CbGeAlD
Nilotinib—EPHB6—myometrium—ovarian cancer	0.000805	0.00532	CbGeAlD
Nilotinib—MAPK8—bone marrow—ovarian cancer	0.000805	0.00532	CbGeAlD
Nilotinib—BRAF—uterus—ovarian cancer	0.000789	0.00521	CbGeAlD
Nilotinib—EPHB3—uterus—ovarian cancer	0.000782	0.00517	CbGeAlD
Nilotinib—HCK—endometrium—ovarian cancer	0.00078	0.00515	CbGeAlD
Nilotinib—MAPK8—female gonad—ovarian cancer	0.000776	0.00512	CbGeAlD
Nilotinib—CA3—uterine cervix—ovarian cancer	0.000774	0.00511	CbGeAlD
Nilotinib—MAPK8—vagina—ovarian cancer	0.000771	0.00509	CbGeAlD
Nilotinib—MAPK11—testis—ovarian cancer	0.000767	0.00507	CbGeAlD
Nilotinib—CDC42BPB—testis—ovarian cancer	0.000761	0.00503	CbGeAlD
Nilotinib—TIE1—female reproductive system—ovarian cancer	0.000739	0.00488	CbGeAlD
Nilotinib—PDGFRA—embryo—ovarian cancer	0.000734	0.00485	CbGeAlD
Nilotinib—MAP4K1—bone marrow—ovarian cancer	0.000732	0.00483	CbGeAlD
Nilotinib—MAPK14—epithelium—ovarian cancer	0.000729	0.00481	CbGeAlD
Nilotinib—MAPK14—uterine cervix—ovarian cancer	0.000723	0.00477	CbGeAlD
Nilotinib—EPHA3—testis—ovarian cancer	0.000721	0.00476	CbGeAlD
Nilotinib—LCK—uterine cervix—ovarian cancer	0.00072	0.00475	CbGeAlD
Nilotinib—HCK—uterus—ovarian cancer	0.000719	0.00475	CbGeAlD
Nilotinib—EPHB3—female reproductive system—ovarian cancer	0.000703	0.00464	CbGeAlD
Nilotinib—MAP4K1—vagina—ovarian cancer	0.000701	0.00463	CbGeAlD
Nilotinib—EPHB4—epithelium—ovarian cancer	0.000691	0.00456	CbGeAlD
Nilotinib—MAP2K5—myometrium—ovarian cancer	0.000689	0.00455	CbGeAlD
Nilotinib—MAPK14—decidua—ovarian cancer	0.000689	0.00455	CbGeAlD
Nilotinib—EPHA6—testis—ovarian cancer	0.000688	0.00454	CbGeAlD
Nilotinib—MAPK8—testis—ovarian cancer	0.000688	0.00454	CbGeAlD
Nilotinib—FGR—decidua—ovarian cancer	0.000686	0.00453	CbGeAlD
Nilotinib—LCK—decidua—ovarian cancer	0.000686	0.00453	CbGeAlD
Nilotinib—EPHB4—uterine cervix—ovarian cancer	0.000685	0.00452	CbGeAlD
Nilotinib—EPHA2—epithelium—ovarian cancer	0.000678	0.00448	CbGeAlD
Nilotinib—TIE1—female gonad—ovarian cancer	0.000673	0.00444	CbGeAlD
Nilotinib—EPHA2—uterine cervix—ovarian cancer	0.000672	0.00444	CbGeAlD
Nilotinib—CSF1R—myometrium—ovarian cancer	0.000672	0.00444	CbGeAlD
Nilotinib—BRAF—bone marrow—ovarian cancer	0.000669	0.00442	CbGeAlD
Nilotinib—TEK—epithelium—ovarian cancer	0.000661	0.00437	CbGeAlD
Nilotinib—EPHA4—gonad—ovarian cancer	0.000658	0.00434	CbGeAlD
Nilotinib—EPHA4—uterus—ovarian cancer	0.000653	0.00431	CbGeAlD
Nilotinib—EPHB4—decidua—ovarian cancer	0.000653	0.00431	CbGeAlD
Nilotinib—FGR—endometrium—ovarian cancer	0.000651	0.0043	CbGeAlD
Nilotinib—CSF1R—embryo—ovarian cancer	0.000646	0.00427	CbGeAlD
Nilotinib—CA3—uterus—ovarian cancer	0.000645	0.00426	CbGeAlD
Nilotinib—BRAF—female gonad—ovarian cancer	0.000645	0.00426	CbGeAlD
Nilotinib—BRAF—vagina—ovarian cancer	0.000641	0.00423	CbGeAlD
Nilotinib—EPHA2—decidua—ovarian cancer	0.00064	0.00423	CbGeAlD
Nilotinib—EPHB3—female gonad—ovarian cancer	0.00064	0.00423	CbGeAlD
Nilotinib—EPHB3—vagina—ovarian cancer	0.000636	0.0042	CbGeAlD
Nilotinib—BLK—lymph node—ovarian cancer	0.000631	0.00417	CbGeAlD
Nilotinib—EPHB6—uterine cervix—ovarian cancer	0.000627	0.00414	CbGeAlD
Nilotinib—MAP4K1—testis—ovarian cancer	0.000625	0.00413	CbGeAlD
Nilotinib—TEK—decidua—ovarian cancer	0.000625	0.00413	CbGeAlD
Nilotinib—EPHB4—endometrium—ovarian cancer	0.00062	0.00409	CbGeAlD
Nilotinib—KIT—myometrium—ovarian cancer	0.00061	0.00403	CbGeAlD
Nilotinib—HCK—bone marrow—ovarian cancer	0.00061	0.00403	CbGeAlD
Nilotinib—EPHA2—endometrium—ovarian cancer	0.000608	0.00401	CbGeAlD
Nilotinib—MAPK14—uterus—ovarian cancer	0.000602	0.00398	CbGeAlD
Nilotinib—LCK—uterus—ovarian cancer	0.0006	0.00396	CbGeAlD
Nilotinib—EPHB6—decidua—ovarian cancer	0.000597	0.00394	CbGeAlD
Nilotinib—TIE1—testis—ovarian cancer	0.000597	0.00394	CbGeAlD
Nilotinib—PDGFRB—myometrium—ovarian cancer	0.000596	0.00394	CbGeAlD
Nilotinib—TEK—endometrium—ovarian cancer	0.000593	0.00392	CbGeAlD
Nilotinib—HCK—female gonad—ovarian cancer	0.000588	0.00388	CbGeAlD
Nilotinib—EPHA4—female reproductive system—ovarian cancer	0.000587	0.00388	CbGeAlD
Nilotinib—KIT—embryo—ovarian cancer	0.000587	0.00388	CbGeAlD
Nilotinib—HCK—vagina—ovarian cancer	0.000584	0.00386	CbGeAlD
Nilotinib—ABL2—female gonad—ovarian cancer	0.000584	0.00386	CbGeAlD
Nilotinib—ABL2—vagina—ovarian cancer	0.000581	0.00384	CbGeAlD
Nilotinib—PDGFRB—embryo—ovarian cancer	0.000573	0.00379	CbGeAlD
Nilotinib—BRAF—testis—ovarian cancer	0.000572	0.00378	CbGeAlD
Nilotinib—EPHB4—uterus—ovarian cancer	0.000571	0.00377	CbGeAlD
Nilotinib—EPHB3—testis—ovarian cancer	0.000568	0.00375	CbGeAlD
Nilotinib—EPHB6—endometrium—ovarian cancer	0.000567	0.00374	CbGeAlD
Nilotinib—PDGFRA—decidua—ovarian cancer	0.000566	0.00374	CbGeAlD
Nilotinib—MAPK11—lymph node—ovarian cancer	0.000556	0.00367	CbGeAlD
Nilotinib—CA9—female reproductive system—ovarian cancer	0.000555	0.00367	CbGeAlD
Nilotinib—CDC42BPB—lymph node—ovarian cancer	0.000552	0.00364	CbGeAlD
Nilotinib—CA3—bone marrow—ovarian cancer	0.000548	0.00362	CbGeAlD
Nilotinib—TEK—uterus—ovarian cancer	0.000547	0.00361	CbGeAlD
Nilotinib—MAPK14—female reproductive system—ovarian cancer	0.000542	0.00358	CbGeAlD
Nilotinib—FGR—female reproductive system—ovarian cancer	0.000539	0.00356	CbGeAlD
Nilotinib—MAP2K5—uterine cervix—ovarian cancer	0.000536	0.00354	CbGeAlD
Nilotinib—EPHA4—female gonad—ovarian cancer	0.000534	0.00353	CbGeAlD
Nilotinib—ABL1—myometrium—ovarian cancer	0.000531	0.00351	CbGeAlD
Nilotinib—EPHA4—vagina—ovarian cancer	0.000531	0.00351	CbGeAlD
Nilotinib—CA3—vagina—ovarian cancer	0.000525	0.00347	CbGeAlD
Nilotinib—CSF1R—uterine cervix—ovarian cancer	0.000523	0.00345	CbGeAlD
Nilotinib—EPHA3—lymph node—ovarian cancer	0.000523	0.00345	CbGeAlD
Nilotinib—HCK—testis—ovarian cancer	0.000522	0.00344	CbGeAlD
Nilotinib—ABL2—testis—ovarian cancer	0.000518	0.00342	CbGeAlD
Nilotinib—EPHB4—female reproductive system—ovarian cancer	0.000513	0.00339	CbGeAlD
Nilotinib—MAPK14—bone marrow—ovarian cancer	0.000511	0.00338	CbGeAlD
Nilotinib—ABL1—embryo—ovarian cancer	0.000511	0.00337	CbGeAlD
Nilotinib—MAP2K5—decidua—ovarian cancer	0.000511	0.00337	CbGeAlD
Nilotinib—FGR—bone marrow—ovarian cancer	0.000509	0.00336	CbGeAlD
Nilotinib—LCK—bone marrow—ovarian cancer	0.000509	0.00336	CbGeAlD
Nilotinib—EPHA2—female reproductive system—ovarian cancer	0.000504	0.00333	CbGeAlD
Nilotinib—MAPK8—lymph node—ovarian cancer	0.000499	0.00329	CbGeAlD
Nilotinib—PDGFRA—gonad—ovarian cancer	0.000498	0.00329	CbGeAlD
Nilotinib—CSF1R—decidua—ovarian cancer	0.000498	0.00329	CbGeAlD
Nilotinib—PDGFRA—uterus—ovarian cancer	0.000495	0.00327	CbGeAlD
Nilotinib—MAPK14—female gonad—ovarian cancer	0.000493	0.00325	CbGeAlD
Nilotinib—TEK—female reproductive system—ovarian cancer	0.000491	0.00324	CbGeAlD
Nilotinib—LCK—female gonad—ovarian cancer	0.000491	0.00324	CbGeAlD
Nilotinib—FGR—female gonad—ovarian cancer	0.000491	0.00324	CbGeAlD
Nilotinib—MAPK14—vagina—ovarian cancer	0.00049	0.00323	CbGeAlD
Nilotinib—FGR—vagina—ovarian cancer	0.000488	0.00322	CbGeAlD
Nilotinib—LCK—vagina—ovarian cancer	0.000488	0.00322	CbGeAlD
Nilotinib—MAP2K5—endometrium—ovarian cancer	0.000485	0.0032	CbGeAlD
Nilotinib—EPHB4—bone marrow—ovarian cancer	0.000485	0.0032	CbGeAlD
Nilotinib—Ponatinib—ABCB1—ovarian cancer	0.00048	0.619	CrCbGaD
Nilotinib—KIT—epithelium—ovarian cancer	0.000479	0.00316	CbGeAlD
Nilotinib—KIT—uterine cervix—ovarian cancer	0.000475	0.00314	CbGeAlD
Nilotinib—EPHA4—testis—ovarian cancer	0.000474	0.00313	CbGeAlD
Nilotinib—CSF1R—endometrium—ovarian cancer	0.000473	0.00312	CbGeAlD
Nilotinib—CA3—testis—ovarian cancer	0.000468	0.00309	CbGeAlD
Nilotinib—PDGFRB—epithelium—ovarian cancer	0.000468	0.00309	CbGeAlD
Nilotinib—EPHB4—female gonad—ovarian cancer	0.000467	0.00308	CbGeAlD
Nilotinib—EPHB4—vagina—ovarian cancer	0.000464	0.00307	CbGeAlD
Nilotinib—PDGFRB—uterine cervix—ovarian cancer	0.000464	0.00306	CbGeAlD
Nilotinib—EPHA2—female gonad—ovarian cancer	0.000458	0.00303	CbGeAlD
Nilotinib—EPHA2—vagina—ovarian cancer	0.000455	0.00301	CbGeAlD
Nilotinib—MAP4K1—lymph node—ovarian cancer	0.000453	0.00299	CbGeAlD
Nilotinib—KIT—decidua—ovarian cancer	0.000453	0.00299	CbGeAlD
Nilotinib—CA9—testis—ovarian cancer	0.000448	0.00296	CbGeAlD
Nilotinib—TEK—female gonad—ovarian cancer	0.000447	0.00295	CbGeAlD
Nilotinib—PDGFRA—female reproductive system—ovarian cancer	0.000445	0.00294	CbGeAlD
Nilotinib—PDGFRB—decidua—ovarian cancer	0.000442	0.00292	CbGeAlD
Nilotinib—CSF1R—gonad—ovarian cancer	0.000439	0.0029	CbGeAlD
Nilotinib—MAPK14—testis—ovarian cancer	0.000437	0.00289	CbGeAlD
Nilotinib—CSF1R—uterus—ovarian cancer	0.000436	0.00288	CbGeAlD
Nilotinib—FGR—testis—ovarian cancer	0.000435	0.00287	CbGeAlD
Nilotinib—LCK—testis—ovarian cancer	0.000435	0.00287	CbGeAlD
Nilotinib—TIE1—lymph node—ovarian cancer	0.000433	0.00286	CbGeAlD
Nilotinib—KIT—endometrium—ovarian cancer	0.00043	0.00284	CbGeAlD
Nilotinib—EPHB6—female gonad—ovarian cancer	0.000427	0.00282	CbGeAlD
Nilotinib—EPHB6—vagina—ovarian cancer	0.000425	0.0028	CbGeAlD
Nilotinib—PDGFRB—endometrium—ovarian cancer	0.00042	0.00277	CbGeAlD
Nilotinib—BRAF—lymph node—ovarian cancer	0.000415	0.00274	CbGeAlD
Nilotinib—EPHB4—testis—ovarian cancer	0.000414	0.00274	CbGeAlD
Nilotinib—ABL1—uterine cervix—ovarian cancer	0.000413	0.00273	CbGeAlD
Nilotinib—EPHB3—lymph node—ovarian cancer	0.000411	0.00272	CbGeAlD
Nilotinib—CA12—female reproductive system—ovarian cancer	0.000411	0.00271	CbGeAlD
Nilotinib—EPHA2—testis—ovarian cancer	0.000406	0.00268	CbGeAlD
Nilotinib—PDGFRA—female gonad—ovarian cancer	0.000405	0.00267	CbGeAlD
Nilotinib—PDGFRA—vagina—ovarian cancer	0.000403	0.00266	CbGeAlD
Nilotinib—MAP2K5—female reproductive system—ovarian cancer	0.000402	0.00265	CbGeAlD
Nilotinib—KIT—gonad—ovarian cancer	0.000398	0.00263	CbGeAlD
Nilotinib—TEK—testis—ovarian cancer	0.000397	0.00262	CbGeAlD
Nilotinib—KIT—uterus—ovarian cancer	0.000396	0.00261	CbGeAlD
Nilotinib—ABL1—decidua—ovarian cancer	0.000394	0.0026	CbGeAlD
Nilotinib—CSF1R—female reproductive system—ovarian cancer	0.000392	0.00259	CbGeAlD
Nilotinib—PDGFRB—gonad—ovarian cancer	0.000389	0.00257	CbGeAlD
Nilotinib—PDGFRB—uterus—ovarian cancer	0.000387	0.00255	CbGeAlD
Nilotinib—EPHB6—testis—ovarian cancer	0.000379	0.0025	CbGeAlD
Nilotinib—HCK—lymph node—ovarian cancer	0.000378	0.0025	CbGeAlD
Nilotinib—ABL2—lymph node—ovarian cancer	0.000376	0.00248	CbGeAlD
Nilotinib—ABL1—endometrium—ovarian cancer	0.000374	0.00247	CbGeAlD
Nilotinib—CSF1R—bone marrow—ovarian cancer	0.00037	0.00244	CbGeAlD
Nilotinib—MAP2K5—female gonad—ovarian cancer	0.000365	0.00241	CbGeAlD
Nilotinib—MAP2K5—vagina—ovarian cancer	0.000363	0.0024	CbGeAlD
Nilotinib—PDGFRA—testis—ovarian cancer	0.000359	0.00237	CbGeAlD
Nilotinib—CSF1R—female gonad—ovarian cancer	0.000357	0.00235	CbGeAlD
Nilotinib—KIT—female reproductive system—ovarian cancer	0.000356	0.00235	CbGeAlD
Nilotinib—CSF1R—vagina—ovarian cancer	0.000354	0.00234	CbGeAlD
Nilotinib—CA2—embryo—ovarian cancer	0.000348	0.0023	CbGeAlD
Nilotinib—PDGFRB—female reproductive system—ovarian cancer	0.000348	0.0023	CbGeAlD
Nilotinib—ABL1—gonad—ovarian cancer	0.000347	0.00229	CbGeAlD
Nilotinib—ABL1—uterus—ovarian cancer	0.000345	0.00228	CbGeAlD
Nilotinib—EPHA4—lymph node—ovarian cancer	0.000344	0.00227	CbGeAlD
Nilotinib—CA3—lymph node—ovarian cancer	0.000339	0.00224	CbGeAlD
Nilotinib—KIT—bone marrow—ovarian cancer	0.000336	0.00222	CbGeAlD
Nilotinib—ABCG2—myometrium—ovarian cancer	0.000335	0.00221	CbGeAlD
Nilotinib—PDGFRB—bone marrow—ovarian cancer	0.000328	0.00217	CbGeAlD
Nilotinib—CA1—female reproductive system—ovarian cancer	0.000325	0.00215	CbGeAlD
Nilotinib—MAP2K5—testis—ovarian cancer	0.000324	0.00214	CbGeAlD
Nilotinib—KIT—female gonad—ovarian cancer	0.000324	0.00214	CbGeAlD
Nilotinib—KIT—vagina—ovarian cancer	0.000322	0.00213	CbGeAlD
Nilotinib—MAPK14—lymph node—ovarian cancer	0.000317	0.00209	CbGeAlD
Nilotinib—CSF1R—testis—ovarian cancer	0.000316	0.00209	CbGeAlD
Nilotinib—PDGFRB—female gonad—ovarian cancer	0.000316	0.00209	CbGeAlD
Nilotinib—FGR—lymph node—ovarian cancer	0.000316	0.00208	CbGeAlD
Nilotinib—LCK—lymph node—ovarian cancer	0.000316	0.00208	CbGeAlD
Nilotinib—PDGFRB—vagina—ovarian cancer	0.000314	0.00208	CbGeAlD
Nilotinib—ABL1—female reproductive system—ovarian cancer	0.00031	0.00205	CbGeAlD
Nilotinib—CA1—bone marrow—ovarian cancer	0.000307	0.00203	CbGeAlD
Nilotinib—EPHB4—lymph node—ovarian cancer	0.0003	0.00198	CbGeAlD
Nilotinib—Imatinib—ABCB1—ovarian cancer	0.000296	0.381	CrCbGaD
Nilotinib—EPHA2—lymph node—ovarian cancer	0.000295	0.00195	CbGeAlD
Nilotinib—ABL1—bone marrow—ovarian cancer	0.000292	0.00193	CbGeAlD
Nilotinib—TEK—lymph node—ovarian cancer	0.000287	0.0019	CbGeAlD
Nilotinib—KIT—testis—ovarian cancer	0.000287	0.0019	CbGeAlD
Nilotinib—CA2—epithelium—ovarian cancer	0.000284	0.00188	CbGeAlD
Nilotinib—ABL1—female gonad—ovarian cancer	0.000282	0.00186	CbGeAlD
Nilotinib—PDGFRB—testis—ovarian cancer	0.00028	0.00185	CbGeAlD
Nilotinib—ABL1—vagina—ovarian cancer	0.00028	0.00185	CbGeAlD
Nilotinib—EPHB6—lymph node—ovarian cancer	0.000275	0.00181	CbGeAlD
Nilotinib—CA2—decidua—ovarian cancer	0.000268	0.00177	CbGeAlD
Nilotinib—ABCG2—uterine cervix—ovarian cancer	0.000261	0.00172	CbGeAlD
Nilotinib—PDGFRA—lymph node—ovarian cancer	0.00026	0.00172	CbGeAlD
Nilotinib—CA4—female reproductive system—ovarian cancer	0.000254	0.00168	CbGeAlD
Nilotinib—ABL1—testis—ovarian cancer	0.00025	0.00165	CbGeAlD
Nilotinib—ABCG2—decidua—ovarian cancer	0.000248	0.00164	CbGeAlD
Nilotinib—CYP2C8—endometrium—ovarian cancer	0.000243	0.0016	CbGeAlD
Nilotinib—CA4—bone marrow—ovarian cancer	0.00024	0.00159	CbGeAlD
Nilotinib—ABCG2—endometrium—ovarian cancer	0.000236	0.00156	CbGeAlD
Nilotinib—MAP2K5—lymph node—ovarian cancer	0.000235	0.00155	CbGeAlD
Nilotinib—CA4—female gonad—ovarian cancer	0.000231	0.00153	CbGeAlD
Nilotinib—CSF1R—lymph node—ovarian cancer	0.000229	0.00151	CbGeAlD
Nilotinib—ABL1—Daunorubicin—Epirubicin—ovarian cancer	0.000223	0.0454	CbGdCrCtD
Nilotinib—ABL1—Doxorubicin—Epirubicin—ovarian cancer	0.000223	0.0454	CbGdCrCtD
Nilotinib—ABL1—Idarubicin—Epirubicin—ovarian cancer	0.000223	0.0454	CbGdCrCtD
Nilotinib—ABCG2—uterus—ovarian cancer	0.000217	0.00144	CbGeAlD
Nilotinib—CA2—female reproductive system—ovarian cancer	0.000211	0.00139	CbGeAlD
Nilotinib—KIT—lymph node—ovarian cancer	0.000208	0.00137	CbGeAlD
Nilotinib—ABL1—Idarubicin—Doxorubicin—ovarian cancer	0.000206	0.042	CbGdCrCtD
Nilotinib—ABL1—Epirubicin—Doxorubicin—ovarian cancer	0.000206	0.042	CbGdCrCtD
Nilotinib—ABL1—Daunorubicin—Doxorubicin—ovarian cancer	0.000206	0.042	CbGdCrCtD
Nilotinib—CA4—testis—ovarian cancer	0.000205	0.00136	CbGeAlD
Nilotinib—PDGFRB—lymph node—ovarian cancer	0.000203	0.00134	CbGeAlD
Nilotinib—CYP2B6—gonad—ovarian cancer	0.000202	0.00133	CbGeAlD
Nilotinib—CYP2C8—female reproductive system—ovarian cancer	0.000201	0.00133	CbGeAlD
Nilotinib—CA2—bone marrow—ovarian cancer	0.000199	0.00132	CbGeAlD
Nilotinib—CA2—female gonad—ovarian cancer	0.000192	0.00127	CbGeAlD
Nilotinib—CA2—vagina—ovarian cancer	0.000191	0.00126	CbGeAlD
Nilotinib—CA1—lymph node—ovarian cancer	0.00019	0.00126	CbGeAlD
Nilotinib—ABCG2—bone marrow—ovarian cancer	0.000184	0.00122	CbGeAlD
Nilotinib—CYP2C8—vagina—ovarian cancer	0.000182	0.0012	CbGeAlD
Nilotinib—ABL1—lymph node—ovarian cancer	0.000181	0.0012	CbGeAlD
Nilotinib—CYP2B6—female reproductive system—ovarian cancer	0.00018	0.00119	CbGeAlD
Nilotinib—CYP2C9—female reproductive system—ovarian cancer	0.000178	0.00118	CbGeAlD
Nilotinib—ABCG2—female gonad—ovarian cancer	0.000178	0.00117	CbGeAlD
Nilotinib—ABCG2—vagina—ovarian cancer	0.000177	0.00117	CbGeAlD
Nilotinib—CA2—testis—ovarian cancer	0.00017	0.00112	CbGeAlD
Nilotinib—ABCB1—myometrium—ovarian cancer	0.000165	0.00109	CbGeAlD
Nilotinib—CYP2B6—vagina—ovarian cancer	0.000163	0.00108	CbGeAlD
Nilotinib—CYP2C8—testis—ovarian cancer	0.000162	0.00107	CbGeAlD
Nilotinib—ABCB1—embryo—ovarian cancer	0.000159	0.00105	CbGeAlD
Nilotinib—ABCG2—testis—ovarian cancer	0.000158	0.00104	CbGeAlD
Nilotinib—CA4—lymph node—ovarian cancer	0.000149	0.000983	CbGeAlD
Nilotinib—CYP2B6—testis—ovarian cancer	0.000145	0.00096	CbGeAlD
Nilotinib—CYP3A4—female reproductive system—ovarian cancer	0.000136	0.000899	CbGeAlD
Nilotinib—CYP2D6—female reproductive system—ovarian cancer	0.000134	0.000884	CbGeAlD
Nilotinib—ABCB1—epithelium—ovarian cancer	0.00013	0.000856	CbGeAlD
Nilotinib—ABCB1—uterine cervix—ovarian cancer	0.000129	0.000849	CbGeAlD
Nilotinib—CA2—lymph node—ovarian cancer	0.000123	0.000815	CbGeAlD
Nilotinib—ABCB1—decidua—ovarian cancer	0.000122	0.000809	CbGeAlD
Nilotinib—CYP2D6—female gonad—ovarian cancer	0.000122	0.000805	CbGeAlD
Nilotinib—ABCB1—endometrium—ovarian cancer	0.000116	0.000768	CbGeAlD
Nilotinib—ABCG2—lymph node—ovarian cancer	0.000114	0.000755	CbGeAlD
Nilotinib—CYP2D6—testis—ovarian cancer	0.000108	0.000714	CbGeAlD
Nilotinib—ABCB1—gonad—ovarian cancer	0.000108	0.000712	CbGeAlD
Nilotinib—ABCB1—uterus—ovarian cancer	0.000107	0.000708	CbGeAlD
Nilotinib—ABCB1—female reproductive system—ovarian cancer	9.63e-05	0.000636	CbGeAlD
Nilotinib—ABCB1—bone marrow—ovarian cancer	9.09e-05	0.000601	CbGeAlD
Nilotinib—ABCB1—female gonad—ovarian cancer	8.77e-05	0.000579	CbGeAlD
Nilotinib—ABCB1—vagina—ovarian cancer	8.71e-05	0.000575	CbGeAlD
Nilotinib—Stomatitis—Epirubicin—ovarian cancer	8.63e-05	0.000405	CcSEcCtD
Nilotinib—Jaundice—Epirubicin—ovarian cancer	8.63e-05	0.000405	CcSEcCtD
Nilotinib—Conjunctivitis—Epirubicin—ovarian cancer	8.61e-05	0.000404	CcSEcCtD
Nilotinib—Urinary tract infection—Epirubicin—ovarian cancer	8.61e-05	0.000404	CcSEcCtD
Nilotinib—Neutropenia—Doxorubicin—ovarian cancer	8.6e-05	0.000403	CcSEcCtD
Nilotinib—Dysuria—Doxorubicin—ovarian cancer	8.6e-05	0.000403	CcSEcCtD
Nilotinib—Decreased appetite—Paclitaxel—ovarian cancer	8.59e-05	0.000403	CcSEcCtD
Nilotinib—Dry mouth—Docetaxel—ovarian cancer	8.55e-05	0.0004	CcSEcCtD
Nilotinib—Upper respiratory tract infection—Doxorubicin—ovarian cancer	8.54e-05	0.0004	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Paclitaxel—ovarian cancer	8.53e-05	0.0004	CcSEcCtD
Nilotinib—Fatigue—Paclitaxel—ovarian cancer	8.52e-05	0.000399	CcSEcCtD
Nilotinib—Pollakiuria—Doxorubicin—ovarian cancer	8.49e-05	0.000398	CcSEcCtD
Nilotinib—Constipation—Paclitaxel—ovarian cancer	8.45e-05	0.000396	CcSEcCtD
Nilotinib—Pain—Paclitaxel—ovarian cancer	8.45e-05	0.000396	CcSEcCtD
Nilotinib—Haematuria—Epirubicin—ovarian cancer	8.45e-05	0.000396	CcSEcCtD
Nilotinib—Confusional state—Docetaxel—ovarian cancer	8.45e-05	0.000396	CcSEcCtD
Nilotinib—Photosensitivity reaction—Doxorubicin—ovarian cancer	8.39e-05	0.000393	CcSEcCtD
Nilotinib—Hepatobiliary disease—Epirubicin—ovarian cancer	8.38e-05	0.000393	CcSEcCtD
Nilotinib—Oedema—Docetaxel—ovarian cancer	8.38e-05	0.000393	CcSEcCtD
Nilotinib—Weight increased—Doxorubicin—ovarian cancer	8.37e-05	0.000392	CcSEcCtD
Nilotinib—Epistaxis—Epirubicin—ovarian cancer	8.36e-05	0.000392	CcSEcCtD
Nilotinib—Infection—Docetaxel—ovarian cancer	8.32e-05	0.00039	CcSEcCtD
Nilotinib—Weight decreased—Doxorubicin—ovarian cancer	8.32e-05	0.00039	CcSEcCtD
Nilotinib—Hyperglycaemia—Doxorubicin—ovarian cancer	8.29e-05	0.000389	CcSEcCtD
Nilotinib—Pneumonia—Doxorubicin—ovarian cancer	8.24e-05	0.000386	CcSEcCtD
Nilotinib—Shock—Docetaxel—ovarian cancer	8.24e-05	0.000386	CcSEcCtD
Nilotinib—Nervous system disorder—Docetaxel—ovarian cancer	8.21e-05	0.000385	CcSEcCtD
Nilotinib—Thrombocytopenia—Docetaxel—ovarian cancer	8.2e-05	0.000384	CcSEcCtD
Nilotinib—Infestation—Doxorubicin—ovarian cancer	8.2e-05	0.000384	CcSEcCtD
Nilotinib—Infestation NOS—Doxorubicin—ovarian cancer	8.2e-05	0.000384	CcSEcCtD
Nilotinib—Tachycardia—Docetaxel—ovarian cancer	8.18e-05	0.000383	CcSEcCtD
Nilotinib—Feeling abnormal—Paclitaxel—ovarian cancer	8.14e-05	0.000382	CcSEcCtD
Nilotinib—Skin disorder—Docetaxel—ovarian cancer	8.14e-05	0.000381	CcSEcCtD
Nilotinib—Bradycardia—Epirubicin—ovarian cancer	8.1e-05	0.000379	CcSEcCtD
Nilotinib—Gastrointestinal pain—Paclitaxel—ovarian cancer	8.08e-05	0.000379	CcSEcCtD
Nilotinib—Renal failure—Doxorubicin—ovarian cancer	8.06e-05	0.000378	CcSEcCtD
Nilotinib—Neuropathy peripheral—Doxorubicin—ovarian cancer	8.03e-05	0.000377	CcSEcCtD
Nilotinib—Haemoglobin—Epirubicin—ovarian cancer	7.99e-05	0.000375	CcSEcCtD
Nilotinib—Stomatitis—Doxorubicin—ovarian cancer	7.99e-05	0.000374	CcSEcCtD
Nilotinib—Jaundice—Doxorubicin—ovarian cancer	7.99e-05	0.000374	CcSEcCtD
Nilotinib—Anorexia—Docetaxel—ovarian cancer	7.98e-05	0.000374	CcSEcCtD
Nilotinib—Rhinitis—Epirubicin—ovarian cancer	7.97e-05	0.000374	CcSEcCtD
Nilotinib—Conjunctivitis—Doxorubicin—ovarian cancer	7.97e-05	0.000373	CcSEcCtD
Nilotinib—Urinary tract infection—Doxorubicin—ovarian cancer	7.97e-05	0.000373	CcSEcCtD
Nilotinib—Haemorrhage—Epirubicin—ovarian cancer	7.95e-05	0.000373	CcSEcCtD
Nilotinib—Hepatitis—Epirubicin—ovarian cancer	7.95e-05	0.000373	CcSEcCtD
Nilotinib—Hypoaesthesia—Epirubicin—ovarian cancer	7.91e-05	0.000371	CcSEcCtD
Nilotinib—Pharyngitis—Epirubicin—ovarian cancer	7.89e-05	0.00037	CcSEcCtD
Nilotinib—Urinary tract disorder—Epirubicin—ovarian cancer	7.85e-05	0.000368	CcSEcCtD
Nilotinib—Urticaria—Paclitaxel—ovarian cancer	7.85e-05	0.000368	CcSEcCtD
Nilotinib—Oedema peripheral—Epirubicin—ovarian cancer	7.83e-05	0.000367	CcSEcCtD
Nilotinib—Hypotension—Docetaxel—ovarian cancer	7.83e-05	0.000367	CcSEcCtD
Nilotinib—Haematuria—Doxorubicin—ovarian cancer	7.82e-05	0.000366	CcSEcCtD
Nilotinib—Connective tissue disorder—Epirubicin—ovarian cancer	7.81e-05	0.000366	CcSEcCtD
Nilotinib—Abdominal pain—Paclitaxel—ovarian cancer	7.81e-05	0.000366	CcSEcCtD
Nilotinib—Body temperature increased—Paclitaxel—ovarian cancer	7.81e-05	0.000366	CcSEcCtD
Nilotinib—Urethral disorder—Epirubicin—ovarian cancer	7.8e-05	0.000365	CcSEcCtD
Nilotinib—ABCB1—testis—ovarian cancer	7.77e-05	0.000513	CbGeAlD
Nilotinib—Hepatobiliary disease—Doxorubicin—ovarian cancer	7.75e-05	0.000363	CcSEcCtD
Nilotinib—Epistaxis—Doxorubicin—ovarian cancer	7.73e-05	0.000362	CcSEcCtD
Nilotinib—Visual impairment—Epirubicin—ovarian cancer	7.66e-05	0.000359	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Docetaxel—ovarian cancer	7.63e-05	0.000358	CcSEcCtD
Nilotinib—Insomnia—Docetaxel—ovarian cancer	7.58e-05	0.000355	CcSEcCtD
Nilotinib—Paraesthesia—Docetaxel—ovarian cancer	7.52e-05	0.000352	CcSEcCtD
Nilotinib—Erythema multiforme—Epirubicin—ovarian cancer	7.52e-05	0.000352	CcSEcCtD
Nilotinib—Bradycardia—Doxorubicin—ovarian cancer	7.49e-05	0.000351	CcSEcCtD
Nilotinib—Dyspnoea—Docetaxel—ovarian cancer	7.47e-05	0.00035	CcSEcCtD
Nilotinib—Eye disorder—Epirubicin—ovarian cancer	7.43e-05	0.000348	CcSEcCtD
Nilotinib—Tinnitus—Epirubicin—ovarian cancer	7.41e-05	0.000347	CcSEcCtD
Nilotinib—Haemoglobin—Doxorubicin—ovarian cancer	7.4e-05	0.000347	CcSEcCtD
Nilotinib—Cardiac disorder—Epirubicin—ovarian cancer	7.38e-05	0.000346	CcSEcCtD
Nilotinib—Flushing—Epirubicin—ovarian cancer	7.38e-05	0.000346	CcSEcCtD
Nilotinib—Rhinitis—Doxorubicin—ovarian cancer	7.38e-05	0.000346	CcSEcCtD
Nilotinib—Dyspepsia—Docetaxel—ovarian cancer	7.37e-05	0.000346	CcSEcCtD
Nilotinib—Hepatitis—Doxorubicin—ovarian cancer	7.36e-05	0.000345	CcSEcCtD
Nilotinib—Haemorrhage—Doxorubicin—ovarian cancer	7.36e-05	0.000345	CcSEcCtD
Nilotinib—Hypoaesthesia—Doxorubicin—ovarian cancer	7.32e-05	0.000343	CcSEcCtD
Nilotinib—Pharyngitis—Doxorubicin—ovarian cancer	7.3e-05	0.000342	CcSEcCtD
Nilotinib—Decreased appetite—Docetaxel—ovarian cancer	7.28e-05	0.000341	CcSEcCtD
Nilotinib—Hypersensitivity—Paclitaxel—ovarian cancer	7.28e-05	0.000341	CcSEcCtD
Nilotinib—Urinary tract disorder—Doxorubicin—ovarian cancer	7.27e-05	0.000341	CcSEcCtD
Nilotinib—Oedema peripheral—Doxorubicin—ovarian cancer	7.25e-05	0.00034	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Docetaxel—ovarian cancer	7.23e-05	0.000339	CcSEcCtD
Nilotinib—Connective tissue disorder—Doxorubicin—ovarian cancer	7.23e-05	0.000339	CcSEcCtD
Nilotinib—Fatigue—Docetaxel—ovarian cancer	7.22e-05	0.000338	CcSEcCtD
Nilotinib—Angiopathy—Epirubicin—ovarian cancer	7.21e-05	0.000338	CcSEcCtD
Nilotinib—Urethral disorder—Doxorubicin—ovarian cancer	7.21e-05	0.000338	CcSEcCtD
Nilotinib—Immune system disorder—Epirubicin—ovarian cancer	7.18e-05	0.000337	CcSEcCtD
Nilotinib—Mediastinal disorder—Epirubicin—ovarian cancer	7.17e-05	0.000336	CcSEcCtD
Nilotinib—Constipation—Docetaxel—ovarian cancer	7.16e-05	0.000336	CcSEcCtD
Nilotinib—Pain—Docetaxel—ovarian cancer	7.16e-05	0.000336	CcSEcCtD
Nilotinib—Chills—Epirubicin—ovarian cancer	7.14e-05	0.000334	CcSEcCtD
Nilotinib—Arrhythmia—Epirubicin—ovarian cancer	7.1e-05	0.000333	CcSEcCtD
Nilotinib—Visual impairment—Doxorubicin—ovarian cancer	7.09e-05	0.000332	CcSEcCtD
Nilotinib—Asthenia—Paclitaxel—ovarian cancer	7.09e-05	0.000332	CcSEcCtD
Nilotinib—Alopecia—Epirubicin—ovarian cancer	7.03e-05	0.000329	CcSEcCtD
Nilotinib—Pruritus—Paclitaxel—ovarian cancer	6.99e-05	0.000328	CcSEcCtD
Nilotinib—Mental disorder—Epirubicin—ovarian cancer	6.97e-05	0.000326	CcSEcCtD
Nilotinib—Erythema multiforme—Doxorubicin—ovarian cancer	6.96e-05	0.000326	CcSEcCtD
Nilotinib—Erythema—Epirubicin—ovarian cancer	6.92e-05	0.000324	CcSEcCtD
Nilotinib—Malnutrition—Epirubicin—ovarian cancer	6.92e-05	0.000324	CcSEcCtD
Nilotinib—Feeling abnormal—Docetaxel—ovarian cancer	6.9e-05	0.000323	CcSEcCtD
Nilotinib—Eye disorder—Doxorubicin—ovarian cancer	6.88e-05	0.000322	CcSEcCtD
Nilotinib—Tinnitus—Doxorubicin—ovarian cancer	6.86e-05	0.000321	CcSEcCtD
Nilotinib—Gastrointestinal pain—Docetaxel—ovarian cancer	6.85e-05	0.000321	CcSEcCtD
Nilotinib—Flushing—Doxorubicin—ovarian cancer	6.83e-05	0.00032	CcSEcCtD
Nilotinib—Cardiac disorder—Doxorubicin—ovarian cancer	6.83e-05	0.00032	CcSEcCtD
Nilotinib—Flatulence—Epirubicin—ovarian cancer	6.82e-05	0.00032	CcSEcCtD
Nilotinib—Dysgeusia—Epirubicin—ovarian cancer	6.78e-05	0.000318	CcSEcCtD
Nilotinib—Diarrhoea—Paclitaxel—ovarian cancer	6.76e-05	0.000317	CcSEcCtD
Nilotinib—Back pain—Epirubicin—ovarian cancer	6.7e-05	0.000314	CcSEcCtD
Nilotinib—Angiopathy—Doxorubicin—ovarian cancer	6.68e-05	0.000313	CcSEcCtD
Nilotinib—Muscle spasms—Epirubicin—ovarian cancer	6.66e-05	0.000312	CcSEcCtD
Nilotinib—Immune system disorder—Doxorubicin—ovarian cancer	6.65e-05	0.000311	CcSEcCtD
Nilotinib—Mediastinal disorder—Doxorubicin—ovarian cancer	6.63e-05	0.000311	CcSEcCtD
Nilotinib—Abdominal pain—Docetaxel—ovarian cancer	6.62e-05	0.00031	CcSEcCtD
Nilotinib—Body temperature increased—Docetaxel—ovarian cancer	6.62e-05	0.00031	CcSEcCtD
Nilotinib—Chills—Doxorubicin—ovarian cancer	6.6e-05	0.000309	CcSEcCtD
Nilotinib—Arrhythmia—Doxorubicin—ovarian cancer	6.57e-05	0.000308	CcSEcCtD
Nilotinib—Dizziness—Paclitaxel—ovarian cancer	6.53e-05	0.000306	CcSEcCtD
Nilotinib—Vision blurred—Epirubicin—ovarian cancer	6.52e-05	0.000306	CcSEcCtD
Nilotinib—Alopecia—Doxorubicin—ovarian cancer	6.5e-05	0.000305	CcSEcCtD
Nilotinib—Mental disorder—Doxorubicin—ovarian cancer	6.45e-05	0.000302	CcSEcCtD
Nilotinib—Ill-defined disorder—Epirubicin—ovarian cancer	6.42e-05	0.000301	CcSEcCtD
Nilotinib—Malnutrition—Doxorubicin—ovarian cancer	6.41e-05	0.0003	CcSEcCtD
Nilotinib—Erythema—Doxorubicin—ovarian cancer	6.41e-05	0.0003	CcSEcCtD
Nilotinib—Anaemia—Epirubicin—ovarian cancer	6.4e-05	0.0003	CcSEcCtD
Nilotinib—Flatulence—Doxorubicin—ovarian cancer	6.31e-05	0.000296	CcSEcCtD
Nilotinib—Vomiting—Paclitaxel—ovarian cancer	6.28e-05	0.000294	CcSEcCtD
Nilotinib—Dysgeusia—Doxorubicin—ovarian cancer	6.27e-05	0.000294	CcSEcCtD
Nilotinib—Malaise—Epirubicin—ovarian cancer	6.24e-05	0.000293	CcSEcCtD
Nilotinib—Rash—Paclitaxel—ovarian cancer	6.23e-05	0.000292	CcSEcCtD
Nilotinib—Dermatitis—Paclitaxel—ovarian cancer	6.23e-05	0.000292	CcSEcCtD
Nilotinib—Vertigo—Epirubicin—ovarian cancer	6.22e-05	0.000291	CcSEcCtD
Nilotinib—Syncope—Epirubicin—ovarian cancer	6.21e-05	0.000291	CcSEcCtD
Nilotinib—Leukopenia—Epirubicin—ovarian cancer	6.2e-05	0.00029	CcSEcCtD
Nilotinib—Back pain—Doxorubicin—ovarian cancer	6.2e-05	0.00029	CcSEcCtD
Nilotinib—Headache—Paclitaxel—ovarian cancer	6.19e-05	0.00029	CcSEcCtD
Nilotinib—Hypersensitivity—Docetaxel—ovarian cancer	6.17e-05	0.000289	CcSEcCtD
Nilotinib—Muscle spasms—Doxorubicin—ovarian cancer	6.16e-05	0.000289	CcSEcCtD
Nilotinib—Palpitations—Epirubicin—ovarian cancer	6.12e-05	0.000287	CcSEcCtD
Nilotinib—Loss of consciousness—Epirubicin—ovarian cancer	6.08e-05	0.000285	CcSEcCtD
Nilotinib—Cough—Epirubicin—ovarian cancer	6.04e-05	0.000283	CcSEcCtD
Nilotinib—Vision blurred—Doxorubicin—ovarian cancer	6.04e-05	0.000283	CcSEcCtD
Nilotinib—Asthenia—Docetaxel—ovarian cancer	6.01e-05	0.000282	CcSEcCtD
Nilotinib—Hypertension—Epirubicin—ovarian cancer	5.98e-05	0.00028	CcSEcCtD
Nilotinib—Ill-defined disorder—Doxorubicin—ovarian cancer	5.94e-05	0.000278	CcSEcCtD
Nilotinib—Pruritus—Docetaxel—ovarian cancer	5.93e-05	0.000278	CcSEcCtD
Nilotinib—Anaemia—Doxorubicin—ovarian cancer	5.92e-05	0.000277	CcSEcCtD
Nilotinib—Myalgia—Epirubicin—ovarian cancer	5.89e-05	0.000276	CcSEcCtD
Nilotinib—Chest pain—Epirubicin—ovarian cancer	5.89e-05	0.000276	CcSEcCtD
Nilotinib—Arthralgia—Epirubicin—ovarian cancer	5.89e-05	0.000276	CcSEcCtD
Nilotinib—Anxiety—Epirubicin—ovarian cancer	5.87e-05	0.000275	CcSEcCtD
Nilotinib—Nausea—Paclitaxel—ovarian cancer	5.87e-05	0.000275	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	5.85e-05	0.000274	CcSEcCtD
Nilotinib—Discomfort—Epirubicin—ovarian cancer	5.82e-05	0.000273	CcSEcCtD
Nilotinib—Malaise—Doxorubicin—ovarian cancer	5.78e-05	0.000271	CcSEcCtD
Nilotinib—Dry mouth—Epirubicin—ovarian cancer	5.76e-05	0.00027	CcSEcCtD
Nilotinib—Vertigo—Doxorubicin—ovarian cancer	5.75e-05	0.00027	CcSEcCtD
Nilotinib—Syncope—Doxorubicin—ovarian cancer	5.74e-05	0.000269	CcSEcCtD
Nilotinib—Leukopenia—Doxorubicin—ovarian cancer	5.73e-05	0.000269	CcSEcCtD
Nilotinib—Diarrhoea—Docetaxel—ovarian cancer	5.73e-05	0.000269	CcSEcCtD
Nilotinib—Confusional state—Epirubicin—ovarian cancer	5.7e-05	0.000267	CcSEcCtD
Nilotinib—Palpitations—Doxorubicin—ovarian cancer	5.66e-05	0.000265	CcSEcCtD
Nilotinib—Oedema—Epirubicin—ovarian cancer	5.65e-05	0.000265	CcSEcCtD
Nilotinib—ABCB1—lymph node—ovarian cancer	5.64e-05	0.000372	CbGeAlD
Nilotinib—Loss of consciousness—Doxorubicin—ovarian cancer	5.63e-05	0.000264	CcSEcCtD
Nilotinib—Infection—Epirubicin—ovarian cancer	5.61e-05	0.000263	CcSEcCtD
Nilotinib—Cough—Doxorubicin—ovarian cancer	5.59e-05	0.000262	CcSEcCtD
Nilotinib—Shock—Epirubicin—ovarian cancer	5.56e-05	0.00026	CcSEcCtD
Nilotinib—Nervous system disorder—Epirubicin—ovarian cancer	5.54e-05	0.00026	CcSEcCtD
Nilotinib—Dizziness—Docetaxel—ovarian cancer	5.54e-05	0.00026	CcSEcCtD
Nilotinib—Thrombocytopenia—Epirubicin—ovarian cancer	5.53e-05	0.000259	CcSEcCtD
Nilotinib—Hypertension—Doxorubicin—ovarian cancer	5.53e-05	0.000259	CcSEcCtD
Nilotinib—Tachycardia—Epirubicin—ovarian cancer	5.51e-05	0.000258	CcSEcCtD
Nilotinib—Skin disorder—Epirubicin—ovarian cancer	5.49e-05	0.000257	CcSEcCtD
Nilotinib—Hyperhidrosis—Epirubicin—ovarian cancer	5.46e-05	0.000256	CcSEcCtD
Nilotinib—Chest pain—Doxorubicin—ovarian cancer	5.45e-05	0.000256	CcSEcCtD
Nilotinib—Arthralgia—Doxorubicin—ovarian cancer	5.45e-05	0.000256	CcSEcCtD
Nilotinib—Myalgia—Doxorubicin—ovarian cancer	5.45e-05	0.000256	CcSEcCtD
Nilotinib—Anxiety—Doxorubicin—ovarian cancer	5.43e-05	0.000255	CcSEcCtD
Nilotinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	5.42e-05	0.000254	CcSEcCtD
Nilotinib—Discomfort—Doxorubicin—ovarian cancer	5.39e-05	0.000252	CcSEcCtD
Nilotinib—Anorexia—Epirubicin—ovarian cancer	5.39e-05	0.000252	CcSEcCtD
Nilotinib—Dry mouth—Doxorubicin—ovarian cancer	5.33e-05	0.00025	CcSEcCtD
Nilotinib—Vomiting—Docetaxel—ovarian cancer	5.33e-05	0.00025	CcSEcCtD
Nilotinib—Rash—Docetaxel—ovarian cancer	5.28e-05	0.000247	CcSEcCtD
Nilotinib—Hypotension—Epirubicin—ovarian cancer	5.28e-05	0.000247	CcSEcCtD
Nilotinib—Dermatitis—Docetaxel—ovarian cancer	5.28e-05	0.000247	CcSEcCtD
Nilotinib—Confusional state—Doxorubicin—ovarian cancer	5.27e-05	0.000247	CcSEcCtD
Nilotinib—Headache—Docetaxel—ovarian cancer	5.25e-05	0.000246	CcSEcCtD
Nilotinib—Oedema—Doxorubicin—ovarian cancer	5.23e-05	0.000245	CcSEcCtD
Nilotinib—Infection—Doxorubicin—ovarian cancer	5.19e-05	0.000243	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Epirubicin—ovarian cancer	5.15e-05	0.000241	CcSEcCtD
Nilotinib—Shock—Doxorubicin—ovarian cancer	5.14e-05	0.000241	CcSEcCtD
Nilotinib—Nervous system disorder—Doxorubicin—ovarian cancer	5.13e-05	0.00024	CcSEcCtD
Nilotinib—Thrombocytopenia—Doxorubicin—ovarian cancer	5.12e-05	0.00024	CcSEcCtD
Nilotinib—Insomnia—Epirubicin—ovarian cancer	5.11e-05	0.000239	CcSEcCtD
Nilotinib—Tachycardia—Doxorubicin—ovarian cancer	5.1e-05	0.000239	CcSEcCtD
Nilotinib—Skin disorder—Doxorubicin—ovarian cancer	5.08e-05	0.000238	CcSEcCtD
Nilotinib—Paraesthesia—Epirubicin—ovarian cancer	5.07e-05	0.000238	CcSEcCtD
Nilotinib—Hyperhidrosis—Doxorubicin—ovarian cancer	5.05e-05	0.000237	CcSEcCtD
Nilotinib—Dyspnoea—Epirubicin—ovarian cancer	5.04e-05	0.000236	CcSEcCtD
Nilotinib—Anorexia—Doxorubicin—ovarian cancer	4.98e-05	0.000234	CcSEcCtD
Nilotinib—Nausea—Docetaxel—ovarian cancer	4.98e-05	0.000233	CcSEcCtD
Nilotinib—Dyspepsia—Epirubicin—ovarian cancer	4.97e-05	0.000233	CcSEcCtD
Nilotinib—Decreased appetite—Epirubicin—ovarian cancer	4.91e-05	0.00023	CcSEcCtD
Nilotinib—Hypotension—Doxorubicin—ovarian cancer	4.88e-05	0.000229	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Epirubicin—ovarian cancer	4.88e-05	0.000229	CcSEcCtD
Nilotinib—Fatigue—Epirubicin—ovarian cancer	4.87e-05	0.000228	CcSEcCtD
Nilotinib—Pain—Epirubicin—ovarian cancer	4.83e-05	0.000226	CcSEcCtD
Nilotinib—Constipation—Epirubicin—ovarian cancer	4.83e-05	0.000226	CcSEcCtD
Nilotinib—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	4.76e-05	0.000223	CcSEcCtD
Nilotinib—Insomnia—Doxorubicin—ovarian cancer	4.73e-05	0.000222	CcSEcCtD
Nilotinib—Paraesthesia—Doxorubicin—ovarian cancer	4.69e-05	0.00022	CcSEcCtD
Nilotinib—Dyspnoea—Doxorubicin—ovarian cancer	4.66e-05	0.000218	CcSEcCtD
Nilotinib—Feeling abnormal—Epirubicin—ovarian cancer	4.66e-05	0.000218	CcSEcCtD
Nilotinib—Gastrointestinal pain—Epirubicin—ovarian cancer	4.62e-05	0.000216	CcSEcCtD
Nilotinib—Dyspepsia—Doxorubicin—ovarian cancer	4.6e-05	0.000216	CcSEcCtD
Nilotinib—Decreased appetite—Doxorubicin—ovarian cancer	4.54e-05	0.000213	CcSEcCtD
Nilotinib—Gastrointestinal disorder—Doxorubicin—ovarian cancer	4.51e-05	0.000211	CcSEcCtD
Nilotinib—Fatigue—Doxorubicin—ovarian cancer	4.51e-05	0.000211	CcSEcCtD
Nilotinib—Urticaria—Epirubicin—ovarian cancer	4.49e-05	0.00021	CcSEcCtD
Nilotinib—Pain—Doxorubicin—ovarian cancer	4.47e-05	0.000209	CcSEcCtD
Nilotinib—Constipation—Doxorubicin—ovarian cancer	4.47e-05	0.000209	CcSEcCtD
Nilotinib—Abdominal pain—Epirubicin—ovarian cancer	4.47e-05	0.000209	CcSEcCtD
Nilotinib—Body temperature increased—Epirubicin—ovarian cancer	4.47e-05	0.000209	CcSEcCtD
Nilotinib—Feeling abnormal—Doxorubicin—ovarian cancer	4.31e-05	0.000202	CcSEcCtD
Nilotinib—Gastrointestinal pain—Doxorubicin—ovarian cancer	4.27e-05	0.0002	CcSEcCtD
Nilotinib—Hypersensitivity—Epirubicin—ovarian cancer	4.16e-05	0.000195	CcSEcCtD
Nilotinib—Urticaria—Doxorubicin—ovarian cancer	4.15e-05	0.000195	CcSEcCtD
Nilotinib—Body temperature increased—Doxorubicin—ovarian cancer	4.13e-05	0.000194	CcSEcCtD
Nilotinib—Abdominal pain—Doxorubicin—ovarian cancer	4.13e-05	0.000194	CcSEcCtD
Nilotinib—Asthenia—Epirubicin—ovarian cancer	4.05e-05	0.00019	CcSEcCtD
Nilotinib—Pruritus—Epirubicin—ovarian cancer	4e-05	0.000187	CcSEcCtD
Nilotinib—Diarrhoea—Epirubicin—ovarian cancer	3.87e-05	0.000181	CcSEcCtD
Nilotinib—Hypersensitivity—Doxorubicin—ovarian cancer	3.85e-05	0.00018	CcSEcCtD
Nilotinib—Asthenia—Doxorubicin—ovarian cancer	3.75e-05	0.000176	CcSEcCtD
Nilotinib—Dizziness—Epirubicin—ovarian cancer	3.74e-05	0.000175	CcSEcCtD
Nilotinib—Pruritus—Doxorubicin—ovarian cancer	3.7e-05	0.000173	CcSEcCtD
Nilotinib—Vomiting—Epirubicin—ovarian cancer	3.59e-05	0.000168	CcSEcCtD
Nilotinib—Diarrhoea—Doxorubicin—ovarian cancer	3.58e-05	0.000168	CcSEcCtD
Nilotinib—Rash—Epirubicin—ovarian cancer	3.56e-05	0.000167	CcSEcCtD
Nilotinib—Dermatitis—Epirubicin—ovarian cancer	3.56e-05	0.000167	CcSEcCtD
Nilotinib—Headache—Epirubicin—ovarian cancer	3.54e-05	0.000166	CcSEcCtD
Nilotinib—Dizziness—Doxorubicin—ovarian cancer	3.46e-05	0.000162	CcSEcCtD
Nilotinib—Nausea—Epirubicin—ovarian cancer	3.36e-05	0.000157	CcSEcCtD
Nilotinib—Vomiting—Doxorubicin—ovarian cancer	3.32e-05	0.000156	CcSEcCtD
Nilotinib—Rash—Doxorubicin—ovarian cancer	3.3e-05	0.000154	CcSEcCtD
Nilotinib—Dermatitis—Doxorubicin—ovarian cancer	3.29e-05	0.000154	CcSEcCtD
Nilotinib—Headache—Doxorubicin—ovarian cancer	3.27e-05	0.000153	CcSEcCtD
Nilotinib—Nausea—Doxorubicin—ovarian cancer	3.11e-05	0.000146	CcSEcCtD
Nilotinib—MAPK14—Signaling Pathways—MTOR—ovarian cancer	2.13e-06	8.49e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CB—ovarian cancer	2.13e-06	8.49e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—IL6—ovarian cancer	2.12e-06	8.48e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MYC—ovarian cancer	2.12e-06	8.47e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PPP2R1A—ovarian cancer	2.12e-06	8.45e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—PIK3CA—ovarian cancer	2.11e-06	8.45e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CD—ovarian cancer	2.11e-06	8.43e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—HRAS—ovarian cancer	2.11e-06	8.42e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CASP3—ovarian cancer	2.11e-06	8.42e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—PIK3CA—ovarian cancer	2.11e-06	8.41e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CDKN1B—ovarian cancer	2.1e-06	8.41e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL2—ovarian cancer	2.1e-06	8.4e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—YAP1—ovarian cancer	2.1e-06	8.39e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK3—ovarian cancer	2.1e-06	8.39e-06	CbGpPWpGaD
Nilotinib—BRAF—Disease—AKT1—ovarian cancer	2.1e-06	8.38e-06	CbGpPWpGaD
Nilotinib—CA9—Metabolism—AKT1—ovarian cancer	2.1e-06	8.38e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	2.1e-06	8.38e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—VEGFA—ovarian cancer	2.1e-06	8.38e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—TP53—ovarian cancer	2.1e-06	8.38e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—MAPK1—ovarian cancer	2.09e-06	8.36e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—EGFR—ovarian cancer	2.09e-06	8.36e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.09e-06	8.34e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—STAT3—ovarian cancer	2.08e-06	8.29e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—MAPK1—ovarian cancer	2.07e-06	8.28e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—EGFR—ovarian cancer	2.07e-06	8.28e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—NRAS—ovarian cancer	2.07e-06	8.27e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—IL6—ovarian cancer	2.07e-06	8.27e-06	CbGpPWpGaD
Nilotinib—KIT—Immune System—AKT1—ovarian cancer	2.07e-06	8.27e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CASP3—ovarian cancer	2.06e-06	8.24e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL2—ovarian cancer	2.06e-06	8.23e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CCND1—ovarian cancer	2.05e-06	8.19e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—HRAS—ovarian cancer	2.05e-06	8.18e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—TYMS—ovarian cancer	2.05e-06	8.18e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CXCL8—ovarian cancer	2.04e-06	8.16e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CG—ovarian cancer	2.04e-06	8.14e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—CTNNB1—ovarian cancer	2.03e-06	8.11e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—STAT3—ovarian cancer	2.03e-06	8.11e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—NRAS—ovarian cancer	2.02e-06	8.09e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—IL6—ovarian cancer	2.02e-06	8.06e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CCND1—ovarian cancer	2.01e-06	8.02e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—HRAS—ovarian cancer	2.01e-06	8.01e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—PIK3CA—ovarian cancer	2e-06	8.01e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—HRAS—ovarian cancer	2e-06	7.98e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—MAPK1—ovarian cancer	2e-06	7.98e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—EGFR—ovarian cancer	2e-06	7.98e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CDKN1B—ovarian cancer	2e-06	7.97e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—PIK3CA—ovarian cancer	1.99e-06	7.97e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MMP9—ovarian cancer	1.99e-06	7.95e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—CTNNB1—ovarian cancer	1.99e-06	7.94e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—VEGFA—ovarian cancer	1.98e-06	7.93e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK3—ovarian cancer	1.98e-06	7.92e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PTEN—ovarian cancer	1.98e-06	7.91e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—KRAS—ovarian cancer	1.98e-06	7.9e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—STAT3—ovarian cancer	1.97e-06	7.85e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—ABCB1—ovarian cancer	1.96e-06	7.85e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—NRAS—ovarian cancer	1.96e-06	7.83e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—IL6—ovarian cancer	1.96e-06	7.83e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Immune System—AKT1—ovarian cancer	1.96e-06	7.82e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—KRAS—ovarian cancer	1.96e-06	7.82e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—HRAS—ovarian cancer	1.96e-06	7.82e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CASP3—ovarian cancer	1.96e-06	7.81e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL2—ovarian cancer	1.95e-06	7.8e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MMP9—ovarian cancer	1.95e-06	7.79e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—ABCB1—ovarian cancer	1.95e-06	7.78e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—HRAS—ovarian cancer	1.95e-06	7.78e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK3—ovarian cancer	1.94e-06	7.74e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PTEN—ovarian cancer	1.94e-06	7.74e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—TYMS—ovarian cancer	1.93e-06	7.71e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MYC—ovarian cancer	1.93e-06	7.71e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—IL6—ovarian cancer	1.92e-06	7.67e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—TYMS—ovarian cancer	1.91e-06	7.64e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—IL6—ovarian cancer	1.91e-06	7.64e-06	CbGpPWpGaD
Nilotinib—KIT—Disease—AKT1—ovarian cancer	1.91e-06	7.63e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CCND1—ovarian cancer	1.9e-06	7.6e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—CAV1—ovarian cancer	1.89e-06	7.57e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—MAPK1—ovarian cancer	1.89e-06	7.54e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—EGFR—ovarian cancer	1.89e-06	7.54e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—KRAS—ovarian cancer	1.89e-06	7.54e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MYC—ovarian cancer	1.89e-06	7.53e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—CTNNB1—ovarian cancer	1.89e-06	7.53e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK3—ovarian cancer	1.88e-06	7.5e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—IL6—ovarian cancer	1.87e-06	7.48e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—IL6—ovarian cancer	1.86e-06	7.45e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—ERBB2—ovarian cancer	1.86e-06	7.44e-06	CbGpPWpGaD
Nilotinib—MAPK8—Signaling Pathways—AKT1—ovarian cancer	1.86e-06	7.44e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—HRAS—ovarian cancer	1.85e-06	7.41e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MMP9—ovarian cancer	1.85e-06	7.38e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—HRAS—ovarian cancer	1.85e-06	7.37e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—MAPK1—ovarian cancer	1.84e-06	7.37e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—EGFR—ovarian cancer	1.84e-06	7.37e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PTEN—ovarian cancer	1.84e-06	7.35e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CB—ovarian cancer	1.84e-06	7.34e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MTOR—ovarian cancer	1.84e-06	7.34e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PTEN—ovarian cancer	1.84e-06	7.34e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MYC—ovarian cancer	1.83e-06	7.29e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—PIK3CA—ovarian cancer	1.82e-06	7.26e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.81e-06	7.23e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Disease—AKT1—ovarian cancer	1.81e-06	7.22e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—PIK3CA—ovarian cancer	1.8e-06	7.19e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CD—ovarian cancer	1.79e-06	7.16e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—VEGFA—ovarian cancer	1.79e-06	7.14e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—MAPK1—ovarian cancer	1.79e-06	7.14e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—EGFR—ovarian cancer	1.79e-06	7.14e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—KRAS—ovarian cancer	1.78e-06	7.12e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—IL6—ovarian cancer	1.78e-06	7.09e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—STAT3—ovarian cancer	1.77e-06	7.07e-06	CbGpPWpGaD
Nilotinib—MAP2K5—Signaling Pathways—AKT1—ovarian cancer	1.77e-06	7.07e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CXCL8—ovarian cancer	1.77e-06	7.06e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—NRAS—ovarian cancer	1.77e-06	7.06e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—IL6—ovarian cancer	1.77e-06	7.05e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Immune System—AKT1—ovarian cancer	1.76e-06	7.05e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—TP53—ovarian cancer	1.76e-06	7.02e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—VEGFA—ovarian cancer	1.75e-06	6.99e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—KRAS—ovarian cancer	1.74e-06	6.96e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—TP53—ovarian cancer	1.74e-06	6.95e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—PIK3CA—ovarian cancer	1.73e-06	6.92e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—STAT3—ovarian cancer	1.73e-06	6.92e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—NRAS—ovarian cancer	1.73e-06	6.91e-06	CbGpPWpGaD
Nilotinib—LYN—Immune System—AKT1—ovarian cancer	1.73e-06	6.9e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CDKN1B—ovarian cancer	1.73e-06	6.89e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CG—ovarian cancer	1.73e-06	6.89e-06	CbGpPWpGaD
Nilotinib—ABL1—Immune System—AKT1—ovarian cancer	1.72e-06	6.87e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—FASN—ovarian cancer	1.71e-06	6.84e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK3—ovarian cancer	1.69e-06	6.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CASP3—ovarian cancer	1.69e-06	6.76e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL2—ovarian cancer	1.69e-06	6.74e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—KRAS—ovarian cancer	1.69e-06	6.74e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.68e-06	6.73e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—HRAS—ovarian cancer	1.68e-06	6.71e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—HRAS—ovarian cancer	1.66e-06	6.65e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—VEGFA—ovarian cancer	1.66e-06	6.63e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK3—ovarian cancer	1.66e-06	6.62e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—CAV1—ovarian cancer	1.65e-06	6.59e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CCND1—ovarian cancer	1.65e-06	6.58e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MYC—ovarian cancer	1.65e-06	6.57e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—STAT3—ovarian cancer	1.64e-06	6.56e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—NRAS—ovarian cancer	1.64e-06	6.55e-06	CbGpPWpGaD
Nilotinib—MAPK14—Immune System—AKT1—ovarian cancer	1.64e-06	6.54e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—PIK3CA—ovarian cancer	1.64e-06	6.54e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—CTNNB1—ovarian cancer	1.63e-06	6.51e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Disease—AKT1—ovarian cancer	1.63e-06	6.51e-06	CbGpPWpGaD
Nilotinib—MAPK14—Gene Expression—AKT1—ovarian cancer	1.63e-06	6.51e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.63e-06	6.5e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MYC—ovarian cancer	1.61e-06	6.43e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—MAPK1—ovarian cancer	1.61e-06	6.43e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—EGFR—ovarian cancer	1.61e-06	6.43e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—IL6—ovarian cancer	1.61e-06	6.42e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—HRAS—ovarian cancer	1.6e-06	6.41e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—PIK3CA—ovarian cancer	1.6e-06	6.39e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MMP9—ovarian cancer	1.6e-06	6.38e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—IL6—ovarian cancer	1.59e-06	6.36e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PTEN—ovarian cancer	1.59e-06	6.35e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—TP53—ovarian cancer	1.58e-06	6.33e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—MAPK1—ovarian cancer	1.58e-06	6.29e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—EGFR—ovarian cancer	1.58e-06	6.29e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK3—ovarian cancer	1.57e-06	6.27e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CB—ovarian cancer	1.56e-06	6.24e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.56e-06	6.23e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—CAV1—ovarian cancer	1.55e-06	6.21e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—PIK3CA—ovarian cancer	1.55e-06	6.19e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—CAV1—ovarian cancer	1.54e-06	6.16e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—IL6—ovarian cancer	1.53e-06	6.13e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—PIK3CA—ovarian cancer	1.53e-06	6.11e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MYC—ovarian cancer	1.53e-06	6.1e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—KRAS—ovarian cancer	1.52e-06	6.07e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CD—ovarian cancer	1.52e-06	6.06e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—HRAS—ovarian cancer	1.52e-06	6.05e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CG—ovarian cancer	1.5e-06	6e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—TP53—ovarian cancer	1.5e-06	5.99e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—MAPK1—ovarian cancer	1.49e-06	5.97e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—EGFR—ovarian cancer	1.49e-06	5.97e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—KRAS—ovarian cancer	1.49e-06	5.95e-06	CbGpPWpGaD
Nilotinib—MAPK11—Signaling Pathways—AKT1—ovarian cancer	1.48e-06	5.93e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—HRAS—ovarian cancer	1.48e-06	5.92e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	1.47e-06	5.88e-06	CbGpPWpGaD
Nilotinib—BRAF—Signaling Pathways—AKT1—ovarian cancer	1.47e-06	5.87e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—IL6—ovarian cancer	1.45e-06	5.79e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—VEGFA—ovarian cancer	1.43e-06	5.73e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—HRAS—ovarian cancer	1.43e-06	5.73e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—STAT3—ovarian cancer	1.42e-06	5.68e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—NRAS—ovarian cancer	1.42e-06	5.66e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—IL6—ovarian cancer	1.42e-06	5.66e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.42e-06	5.66e-06	CbGpPWpGaD
Nilotinib—LCK—Immune System—AKT1—ovarian cancer	1.42e-06	5.66e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—KRAS—ovarian cancer	1.41e-06	5.64e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CG—ovarian cancer	1.4e-06	5.61e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—PIK3CA—ovarian cancer	1.4e-06	5.58e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.38e-06	5.53e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—IL6—ovarian cancer	1.37e-06	5.48e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—PIK3CA—ovarian cancer	1.37e-06	5.46e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK3—ovarian cancer	1.36e-06	5.42e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—TP53—ovarian cancer	1.35e-06	5.4e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PTEN—ovarian cancer	1.35e-06	5.39e-06	CbGpPWpGaD
Nilotinib—KIT—Signaling Pathways—AKT1—ovarian cancer	1.34e-06	5.34e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—TP53—ovarian cancer	1.32e-06	5.28e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CB—ovarian cancer	1.32e-06	5.28e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CD—ovarian cancer	1.32e-06	5.28e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MYC—ovarian cancer	1.32e-06	5.27e-06	CbGpPWpGaD
Nilotinib—LCK—Disease—AKT1—ovarian cancer	1.31e-06	5.22e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—PIK3CA—ovarian cancer	1.3e-06	5.19e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—PIK3CA—ovarian cancer	1.3e-06	5.18e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—HRAS—ovarian cancer	1.29e-06	5.16e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—MAPK1—ovarian cancer	1.29e-06	5.16e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—EGFR—ovarian cancer	1.29e-06	5.16e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.28e-06	5.13e-06	CbGpPWpGaD
Nilotinib—PDGFRA—Signaling Pathways—AKT1—ovarian cancer	1.27e-06	5.06e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—HRAS—ovarian cancer	1.27e-06	5.05e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—TYMS—ovarian cancer	1.26e-06	5.04e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—TP53—ovarian cancer	1.25e-06	5.01e-06	CbGpPWpGaD
Nilotinib—UGT1A1—Metabolism—AKT1—ovarian cancer	1.25e-06	4.99e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.24e-06	4.97e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—IL6—ovarian cancer	1.24e-06	4.94e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CD—ovarian cancer	1.23e-06	4.93e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—KRAS—ovarian cancer	1.22e-06	4.87e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—IL6—ovarian cancer	1.21e-06	4.84e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—HRAS—ovarian cancer	1.2e-06	4.79e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CB—ovarian cancer	1.15e-06	4.6e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—IL6—ovarian cancer	1.15e-06	4.59e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PTEN—ovarian cancer	1.14e-06	4.56e-06	CbGpPWpGaD
Nilotinib—PDGFRB—Signaling Pathways—AKT1—ovarian cancer	1.14e-06	4.56e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—PIK3CA—ovarian cancer	1.12e-06	4.48e-06	CbGpPWpGaD
Nilotinib—LYN—Signaling Pathways—AKT1—ovarian cancer	1.12e-06	4.46e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.09e-06	4.34e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—TP53—ovarian cancer	1.08e-06	4.33e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CB—ovarian cancer	1.08e-06	4.3e-06	CbGpPWpGaD
Nilotinib—ABCG2—Metabolism—AKT1—ovarian cancer	1.06e-06	4.24e-06	CbGpPWpGaD
Nilotinib—MAPK14—Signaling Pathways—AKT1—ovarian cancer	1.06e-06	4.23e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—HRAS—ovarian cancer	1.04e-06	4.14e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—CAV1—ovarian cancer	1.02e-06	4.06e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PTEN—ovarian cancer	9.95e-07	3.98e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—IL6—ovarian cancer	9.92e-07	3.96e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—PIK3CA—ovarian cancer	9.52e-07	3.8e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PTEN—ovarian cancer	9.38e-07	3.75e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PTEN—ovarian cancer	9.3e-07	3.71e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CG—ovarian cancer	9.26e-07	3.7e-06	CbGpPWpGaD
Nilotinib—LCK—Signaling Pathways—AKT1—ovarian cancer	9.16e-07	3.66e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CD—ovarian cancer	8.14e-07	3.25e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—PIK3CA—ovarian cancer	8.06e-07	3.22e-06	CbGpPWpGaD
Nilotinib—CYP2B6—Metabolism—AKT1—ovarian cancer	7.78e-07	3.11e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CB—ovarian cancer	7.09e-07	2.83e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—PIK3CA—ovarian cancer	7.02e-07	2.8e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—PIK3CA—ovarian cancer	6.62e-07	2.64e-06	CbGpPWpGaD
Nilotinib—CYP2C8—Metabolism—AKT1—ovarian cancer	6.58e-07	2.63e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—PIK3CA—ovarian cancer	6.56e-07	2.62e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PTEN—ovarian cancer	6.13e-07	2.45e-06	CbGpPWpGaD
Nilotinib—ABCB1—Metabolism—AKT1—ovarian cancer	5.73e-07	2.29e-06	CbGpPWpGaD
Nilotinib—CYP2D6—Metabolism—AKT1—ovarian cancer	5.4e-07	2.16e-06	CbGpPWpGaD
Nilotinib—CYP2C9—Metabolism—AKT1—ovarian cancer	5.36e-07	2.14e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.33e-07	1.73e-06	CbGpPWpGaD
Nilotinib—CYP3A4—Metabolism—AKT1—ovarian cancer	3.53e-07	1.41e-06	CbGpPWpGaD
